JP2018531938A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531938A5
JP2018531938A5 JP2018517274A JP2018517274A JP2018531938A5 JP 2018531938 A5 JP2018531938 A5 JP 2018531938A5 JP 2018517274 A JP2018517274 A JP 2018517274A JP 2018517274 A JP2018517274 A JP 2018517274A JP 2018531938 A5 JP2018531938 A5 JP 2018531938A5
Authority
JP
Japan
Prior art keywords
arg
seq
trp
phe
hcys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531938A (ja
JP7051106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054455 external-priority patent/WO2017059075A1/en
Publication of JP2018531938A publication Critical patent/JP2018531938A/ja
Publication of JP2018531938A5 publication Critical patent/JP2018531938A5/ja
Application granted granted Critical
Publication of JP7051106B2 publication Critical patent/JP7051106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517274A 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法 Active JP7051106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
PCT/US2016/054455 WO2017059075A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021041611A Division JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法

Publications (3)

Publication Number Publication Date
JP2018531938A JP2018531938A (ja) 2018-11-01
JP2018531938A5 true JP2018531938A5 (enExample) 2019-11-07
JP7051106B2 JP7051106B2 (ja) 2022-04-11

Family

ID=57138146

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2018517274A Active JP7051106B2 (ja) 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法
JP2018517270A Active JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法
JP2021064764A Active JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Pending JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2018517270A Active JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法
JP2021064764A Active JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Pending JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法

Country Status (20)

Country Link
US (5) US10960046B2 (enExample)
EP (4) EP4360704A3 (enExample)
JP (7) JP7051106B2 (enExample)
KR (1) KR20180063221A (enExample)
CN (2) CN108601816A (enExample)
AU (6) AU2016330773A1 (enExample)
BR (1) BR112018006674A2 (enExample)
CA (2) CA3000673A1 (enExample)
DK (1) DK3356386T3 (enExample)
ES (1) ES2985734T3 (enExample)
FI (1) FI3356386T3 (enExample)
HK (1) HK1259424A1 (enExample)
IL (3) IL299541A (enExample)
MA (2) MA43040A (enExample)
MX (2) MX2018003983A (enExample)
PL (1) PL3356386T3 (enExample)
PT (1) PT3356386T (enExample)
SG (1) SG10202101510XA (enExample)
WO (2) WO2017059075A1 (enExample)
ZA (1) ZA201802704B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3988108A1 (en) 2011-12-29 2022-04-27 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US10960046B2 (en) * 2015-09-30 2021-03-30 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
TW201922278A (zh) * 2017-11-15 2019-06-16 美商律森製藥股份有限公司 持續釋放之胜肽調配物
CA3090966A1 (en) 2018-02-20 2019-08-29 Charite - Universitatsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
CA3181543A1 (en) * 2020-05-04 2021-11-11 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
JP2023542985A (ja) * 2020-09-24 2023-10-12 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
IL320947A (en) * 2022-11-18 2025-07-01 Rhythm Pharmaceuticals Inc Methods for treating obesity with an mc4r agonist
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN117143183B (zh) * 2023-08-25 2024-08-16 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
EP1594986B1 (de) 2003-02-19 2011-07-13 Universität Duisburg-Essen Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
MXPA05013951A (es) 2003-06-19 2006-02-24 Lilly Co Eli Agonsita del receptor de la melanocortina 4 (mc4) y sus usos.
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
CA2614678A1 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ligands of melanocortin receptors
RU2380372C2 (ru) * 2005-07-08 2010-01-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2104684A1 (en) 2007-01-18 2009-09-30 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
UY31877A (es) 2008-06-09 2010-01-29 Palatin Technologies Inc Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
MX2010013436A (es) 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
EP2320738A4 (en) 2008-08-29 2011-08-24 Transtech Pharma Inc SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CN102223898A (zh) 2008-11-25 2011-10-19 诺沃—诺迪斯克有限公司 治疗肥胖的肽
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
NZ596617A (en) 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CN102548399A (zh) 2009-08-05 2012-07-04 益普生制药股份有限公司 黑皮质素治疗血脂异常的用途
US8541545B2 (en) 2009-08-31 2013-09-24 Tensive Controls Inc. Stabilized melanocortin ligands
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP3988108A1 (en) * 2011-12-29 2022-04-27 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
TR201815173T4 (tr) * 2013-03-15 2018-11-21 Rhythm Pharmaceuticals Inc Peptit bileşimleri.
ES2825076T3 (es) * 2013-03-15 2021-05-14 Rhythm Pharmaceuticals Inc Composiciones farmacéuticas
US10960046B2 (en) 2015-09-30 2021-03-30 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders

Similar Documents

Publication Publication Date Title
JP2018531938A5 (enExample)
CN101600438B (zh) 疼痛疾病治疗剂
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US20080064743A1 (en) Dry powder compound formulations and uses thereof
JP2015510908A (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
US9566273B2 (en) Nicotinic attenuation of CNS inflammation and autoimmunity
US20080008716A1 (en) Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease
TW201840310A (zh) 急性骨髓性白血病(aml)之新穎組合治療
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
JP2020536854A5 (enExample)
CN103370066B (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
JP2014511365A5 (enExample)
EP2945618A1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
JP5973455B2 (ja) 脱髄疾患の治療薬及び予防薬
RU2012126101A (ru) Полипептидный конъюгат
CN109999019B (zh) 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用
CN107921019B (zh) 2-(5s-甲基-2-氧代-4r-苯基-吡咯烷-1-基)-乙酰胺在治疗病情发作中的应用
Day Amylin analogue as an antidiabetic agent
Hertelendy et al. The effect of chronic adrenergic blockade on the inhibition by epinephrine of growth hormone and insulin release in sheep
CN107617101B (zh) 含唑来膦酸和白细胞介素2的药物组合及其应用
CN110833553A (zh) 吡唑并嘧啶衍生物在治疗Arthus反应的用途
WO2025141472A1 (en) Stable pharmaceutical compositions comprising tirzepatide
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
WO2017114215A1 (zh) 重组人钙调磷酸酶b亚基的应用
WO2023245055A1 (en) Thyroid beta-agonist dosing regimens for the treatment of x-ald